A parallel therapeutic benefit has been observed in breast cancer, where simvastatin‐mediated suppression of senescent cell‐derived IL‐6 secretion mitigates chemoradiotherapy‐induced endocrine resistance, ultimately improving treatment outcomes [516]. Here, IL6 is linked to breast carcinoma.